Spots Global Cancer Trial Database for Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis

Official Title: Treatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot Project

Study ID: NCT00879879

Conditions

Precancerous Condition

Interventions

losartan

Study Description

Brief Summary: RATIONALE: Losartan may be effective in treating patients with idiopathic pulmonary fibrosis. PURPOSE: This clinical trial is studying the side effects of losartan and to see how well it works in treating patients with idiopathic pulmonary fibrosis.

Detailed Description: OBJECTIVES: * Evaluate the effects of losartan potassium on disease progression in patients with idiopathic pulmonary fibrosis. * Determine the safety of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive oral losartan potassium daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo pulmonary function tests with gas diffusion lung volumes, Carbon monoxide diffusing capacity (DLCO) tests, and 6-minute walk tests at baseline and then at 3, 6, 9, and 12 months. Patients also complete baseline/transition dyspnea index questionnaires at baseline and then at 1, 3, 6, 9, and 12 months.